Cargando…
Lung transplantation for COPD/pulmonary emphysema
COPD and α-1 antitrypsin deficiency emphysema remain one of the major indications for lung transplantation. If all other treatment possibilities are exhausted or not possible (including rehabilitation, oxygen therapy, noninvasive ventilation, lung volume reduction), patients may qualify for lung tra...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032585/ https://www.ncbi.nlm.nih.gov/pubmed/36948499 http://dx.doi.org/10.1183/16000617.0116-2022 |
_version_ | 1784910833425317888 |
---|---|
author | Verleden, Geert M. Gottlieb, Jens |
author_facet | Verleden, Geert M. Gottlieb, Jens |
author_sort | Verleden, Geert M. |
collection | PubMed |
description | COPD and α-1 antitrypsin deficiency emphysema remain one of the major indications for lung transplantation. If all other treatment possibilities are exhausted or not possible (including rehabilitation, oxygen therapy, noninvasive ventilation, lung volume reduction), patients may qualify for lung transplantation. Strict selection criteria are implemented with a lot of relative and absolute contraindications. Because of an ongoing donor shortage, only a minority of endstage COPD patients will finally get transplanted. The procedure may involve a single or a double lung transplantation, dependent on the experience of the centre, the waiting list, the availability of donor lungs and the patient's risk–benefit ratio. In general, the life expectancy as well as the health-related quality of life after lung transplantation for COPD are usually increased, and may be somewhat better after double compared with single lung transplantation. Several specific complications can be encountered, such as the development of solid organ cancer and chronic lung allograft dysfunction, which develops in up to 50% of patients within 5 years of their transplant and has a major impact on long-term survival, because of the current inefficient treatment modalities. |
format | Online Article Text |
id | pubmed-10032585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-100325852023-03-23 Lung transplantation for COPD/pulmonary emphysema Verleden, Geert M. Gottlieb, Jens Eur Respir Rev Series COPD and α-1 antitrypsin deficiency emphysema remain one of the major indications for lung transplantation. If all other treatment possibilities are exhausted or not possible (including rehabilitation, oxygen therapy, noninvasive ventilation, lung volume reduction), patients may qualify for lung transplantation. Strict selection criteria are implemented with a lot of relative and absolute contraindications. Because of an ongoing donor shortage, only a minority of endstage COPD patients will finally get transplanted. The procedure may involve a single or a double lung transplantation, dependent on the experience of the centre, the waiting list, the availability of donor lungs and the patient's risk–benefit ratio. In general, the life expectancy as well as the health-related quality of life after lung transplantation for COPD are usually increased, and may be somewhat better after double compared with single lung transplantation. Several specific complications can be encountered, such as the development of solid organ cancer and chronic lung allograft dysfunction, which develops in up to 50% of patients within 5 years of their transplant and has a major impact on long-term survival, because of the current inefficient treatment modalities. European Respiratory Society 2023-03-22 /pmc/articles/PMC10032585/ /pubmed/36948499 http://dx.doi.org/10.1183/16000617.0116-2022 Text en Copyright ©The authors 2023 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Series Verleden, Geert M. Gottlieb, Jens Lung transplantation for COPD/pulmonary emphysema |
title | Lung transplantation for COPD/pulmonary emphysema |
title_full | Lung transplantation for COPD/pulmonary emphysema |
title_fullStr | Lung transplantation for COPD/pulmonary emphysema |
title_full_unstemmed | Lung transplantation for COPD/pulmonary emphysema |
title_short | Lung transplantation for COPD/pulmonary emphysema |
title_sort | lung transplantation for copd/pulmonary emphysema |
topic | Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032585/ https://www.ncbi.nlm.nih.gov/pubmed/36948499 http://dx.doi.org/10.1183/16000617.0116-2022 |
work_keys_str_mv | AT verledengeertm lungtransplantationforcopdpulmonaryemphysema AT gottliebjens lungtransplantationforcopdpulmonaryemphysema |